{
  "pmcid": "12196387",
  "sha256": "86c753ec455511e1d0462b84fdac847b06154874aa1eef16e224d4fc6c9541ae",
  "timestamp_utc": "2025-11-09T23:29:43.592818+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.932473881332545,
    "reading_ease": 20.203039621525733,
    "word_count": 267
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on the Cardioprotective Effects of Ginsenosides Against Anthracycline-Induced Cardiotoxicity"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomised to receive either ginsenosides or a placebo."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants undergoing anthracycline treatment were recruited based on specific eligibility criteria. The study was conducted in a clinical setting."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either ginsenosides or a placebo."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to assess the efficacy of ginsenosides in preventing AIC."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the change in left ventricular ejection fraction (LVEF) over a six-month period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed with sealed envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was maintained for patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised, with 100 assigned to the ginsenoside group and 100 to the placebo group, during the recruitment period from January 2020 to June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis included 98 participants in the ginsenoside group and 97 in the placebo group, following an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The ginsenoside group demonstrated a significant improvement in LVEF compared to the placebo group (mean difference = 5.2%, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were mild, with 3% in the ginsenoside group and 1% in the placebo group experiencing gastrointestinal side effects."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 1,
        "evidence": "The trial was funded by [source of funding]."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}